Caspase inhibitors and uses thereof

Details Caspase inhibitors and uses thereof Caspase inhibitors and uses thereof

2006-09-14

2010-10-05

Lewis, Patrick T (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C514S080000, C514S085000, C514S089000, C514S091000, C514S092000, C514S114000

Reexamination Certificate

active

07807659

ABSTRACT:
The present invention relates to novel classes of compounds of formula I which are caspase and TNF-alpha inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase and TNF-alpha activity and consequently, can be advantageously used as agents against caspase-, interleukin-1-(“IL-1”), apoptosis-, interferon-γ inducing factor-(IGIF), interferon-γ-(“IFN-γ”), or TNF-alpha mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to processes for preparing the compounds of this invention. This invention also relates to methods for inhibiting caspase and TNF-alpha activity and decreasing IGIF production and IFN-γ production and methods for treating caspase-, interleukin-1, apoptosis-, and interferon-γ-, and TNF-alpha mediated diseases using the compounds and compositions of this invention.

REFERENCES:
patent: 5225528 (1993-07-01), Bock et al.
patent: 7410956 (2008-08-01), Mortimore et al.
patent: WO 96/40647 (1996-12-01), None
patent: WO 97/22619 (1997-06-01), None
patent: WO 98/11129 (1998-03-01), None
patent: WO 98/16502 (1998-04-01), None
patent: WO 99/18781 (1999-04-01), None
patent: WO 99/47154 (1999-09-01), None
patent: WO 00/23421 (2000-04-01), None
patent: WO 00/61542 (2000-10-01), None
patent: WO 01/44214 (2001-06-01), None
patent: WO 02/22611 (2002-03-01), None
Dinarello, “Interleukin-18,”Methods, 19(1):121-132 (1999).
D. Boudard et al., “Expression and Activity of Caspases 1 and 3 in Myelodysplastic Syndromes.” Leukemia, 14, 2045-2051 (2000).
Y. Cheng et al., “Caspase Inhibitor Affords Neuroprotection with Delayed Administration in a Rat Model of Neonatal Hypoxic-Ischemic Brain Injury.” J. Clin Invest., 101(9), 1992-1999 (1998).
R. E. Dolle et al., “P1 Aspartate-Based Peptide α-((2,6-Dichlorobenzoyl)oxy)methyl Ketones as Potent Time-Dependent Inhibitors of Interleukin-1β-Converting Enzyme.”J. Med. Chem., 37(5), 563-564 (1994).
N. Droin et al., “Upregulation of CASP Genes in Human Tumor Cells Undergoing Etopside-Induced Apoptosis.”Oncogene, 16, 2885-2894 (1998).
R. E. Ellis et al., “Mechanisms and Functions of Cell Death.”Annu. Rev. Cell Biol., 7, 663-698 (1991).
M. Endres et al., “Attenuation of Delayed Neuronal Death After Mild Focal Ischemia in Mice by Inhibition of the Caspase Family.”Journal of Cerebral Blood Flow and Metabolism, 18, 238-247 (1998).
S. Faderl et al., “Caspase 2 and Caspase 3 as Predictors of Complete Remission and Survival in Adults with Acute Lymphoblastic Leukemia.”Clinical Cancer Research, 5, 4041-4047 (1999).
P. Golstein, “Cell Death in Us and Others.”Science, 281 (Aug. 28, 1998).
S. R. Grobmyer et al., “Peptidomimetic Fluoromethylketone Rescues Mice from Lethal Endotoxic Shock.”Molecular Medicine, 5, 585-594 (1999).
T. E. Hedlund et al., “Fas-Mediated Apoptosis in Seven Human Prostate Cancer Cell Lines: Correlation with Tumor Stage.”The Prostate, 36, 92-101 (1998).
A. Lé´vesque et al., “Improved Fluorescent Bioassay for the Detection of Tumor Necrosis Factor Activity.”Journal of Immunological Methods, 178, 71-76 (1995).
J. Li et al., “The Mechanism of Apoptosis in Human Platelets During Storage.”Transfusion, 40, 1320-1329 (2000).
X-S. Liu et al., “The Significance of Changes in Serum Tumour Necrosis Factor (TNF) Activity in Severely Burned Patients.”Burns, 20(1), 40-44 (1994).
A. M. M. Mjalli et al., “Phenylalkyl Ketones as Potent Reversible Inhibitors of Interleukin-1β Converting Enzyme.”Bioorganic&Medicinal Chemistry Letters, 3(12), 2689-2692 (1993).
S. Natori et al., “Apoptosis of Sinusoidal Endothelial Cells Occurs During Liver Preservation Injury by a Caspase-Dependent Mechanism.”Transplantation, 68(1), 89-96 (1999).
D. W. Nicholson et al., “Identification and Inhibition of the ICE/CED-3 Protease Necessary for Mammalian Apoptosis.”Nature, 376, 37-43 (1995).
N. Özö{umlaut over ( )}ren et al., “The Caspase 9 Inhibitor Z-LEHD-FMK Protects Human Liver Cells While Permitting Death of Cancer Cells Exposed to Tumor Necrosis Factor-related Apoptosis-inducing Ligand.”Cancer Research, 60, 6259-6265 (2000).
T. A. Rano et al., “A Combinatorial Approach for Determining Protease Specificities: Application to Interleukin-1β Converting Enzyme (ICE).”Chemistry&Biology, 4(2), 149-155, (1997).
I. Rodriguez et al., “Systemic Injection of a Tripeptide Inhibits the Intracellular Activation of CPP32-like Proteases In Vivo and Fully Protects Mice Against Fas-mediated Fulminant Liver Destruction and Death.”J. Exp. Med. 184, 2067-2072, (1996).
Y. Sasaki et al., “Immunohistochemical study of Fas, Fas Ligand and Interleukin-1β Converting Enzyme Expression in Human Prostatic Cancer.”British Journal of Urology, 81(6), 852-855 (1998).
G. S. Schierle et al., “Caspase Inhibition Reduces Apoptosis and Increases Survival of Nigral Transplants.”Nature Medicine, 5(1), 97-100 (1999).
N. A. Thornberry, “Caspases: Key Mediators of Apoptosis.”Chemistry&Biology, 5, R97-R103 (1998).
N. A. Thornberry et al., “Caspases: Enemies Within.”Science, 281, 1312-1316 (1998).
N. A. Thornberry et al., “Inactivation of Interleukin-1β Converting Enzyme by Peptide (Acyloxy)methyl Ketones.”Biochemistry, 33, 3934-3940 (1994).
A. G. Yakoviev et al., “Activation of CPP32-like Caspases Contributes to Neuronal Apoptosis and Neurological Dysfunction after Traumatic Brain Injury.”The Journal of Neuroscience, 17(19), 7415-7424 (1997).
H. Yaoita et al., “Attenuation of Ischemia/Reperfusion Injury in Rats by a Caspase Inhibitor.”Circulation, 97(3), 276-281 (1998).
W. Vendeville et al., “Indentification of Inhibitors of an 80 kDa Protease fromTypanosoma cruzithrough the Screening of a Combinatorial Peptide Library.”Chem. Pharm. Bull., 47(2), 194-198 (1999).
Bock et al.,Chemical Abstract, vol. 117; 90798, 1998.
“Alzheimer's Disease: Fact Sheet”, NIH Publication No. 03-3431 (Sep. 2005), Alzheimer's Disease Education & Referral (ADEAR) Center, A Service of the National Institute on Aging, National Institutes of Health, U.S. Dept. of Health and Human Services.
Delagarza, V.Clinical Pharmacology(2003), vol. 68, pp. 1365-1372.
“Dengue Fact Sheet”, Jan. 7, 2005, Department of Health and Human Services, Centers for Disease Control and Prevention, pp. 1-3.
Lopalco, L.Current HIV Research(2004), vol. 2, pp. 127-139.

Affiliated with

Also associated with

Rating

Caspase inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Caspase inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Caspase inhibitors and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4176030